CRISPR Therapeutics (CRSP) PT Lowered to $150 at JMP Securities
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $61.29 +5.45%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
JMP Securities analyst Silvan Tuerkcan lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $150.00 (from $155.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
- SentinelOne Inc (S) PT Raised to $22 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
